| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K79669418 | CTRPv2 | pan-cancer | AAC | 0.017 | 0.7 |
| mRNA | RAF265 | CTRPv2 | pan-cancer | AAC | -0.013 | 0.7 |
| mRNA | BRD-K01737880 | CTRPv2 | pan-cancer | AAC | 0.039 | 0.8 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | 0.0093 | 0.8 |
| mRNA | bafilomycin A1 | CTRPv2 | pan-cancer | AAC | -0.041 | 0.8 |
| mRNA | BRD-K28456706 | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | PD173074 | GDSC1000 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | FGIN-1-27 | CTRPv2 | pan-cancer | AAC | 0.022 | 0.8 |